| Study title |
A Randomized, Double-blind, Dose-ranging, Placebo-controlled, Phase 2a Evaluation of the Safety, Tolerability, and Pharmacokinetics of PLN-74809 in Participants With Primary Sclerosing Cholangitis (PSC) and Suspected Liver Fibrosis (INTEGRIS-PSC) |
| Disease or condition |
Primary sclerosing cholangitis |
| Study type |
Interventional (Clinical Trial) |
| Intervention/treatment |
PLN-74809 or placebo |
| Phase |
3 |
| Study site |
Duke University |
| Study location |
Durham |
| Principal investigator name |
Andrew Muir |
| Study coordinator name and email |
Adele Gaskin, adele.gaskin@duke.edu |
| Phone contact |
919-684-0742 |
| Clinicaltrials.gov link |
https://clinicaltrials.gov/ct2/show/NCT04480840 |
